Patients receive the combination of anti-IL6R (tocilizumab) and ICI (anti-PD-L1, atezolizumab), as well as fractionated stereotactic radiotherapy to induce an abscopal effect designed to release tumor neoantigens, activate T cells, and stimulate their infiltration into the tumor [Ene et al., 2020]. The gene discussed is IL6R; the disease is neoplasm.